Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and if it is accurately predicted ...
3D bio-printed liver model and high-content imaging for evaluating the toxicity effects of compounds
The effectiveness of non-clinical drug safety predictions is enhanced by the adoption of three-dimensional (3D) cellular models. 3D bioprinting enables the generation of complex models with spatial ...
According to a new meta-analysis, acute-on-chronic liver failure (ACLF) can develop even in patients with previously ...
Rochester, Minn.-based Mayo Clinic developed an AI model that identified twice as many cases of advanced chronic liver disease in asymptomatic patients compared to standard diagnostic methods. The ...
GAITHERSBURG, Md., June 05, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflammatory and ...
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of ...
Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.
Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback